Clinical trials: Fertilization
Female Infertility
A Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg Daily Versus Crinone 8% Intravaginal Progesterone Gel 90 mg Daily for Luteal Support in In-Vitro Fertilization (LOTUS II)
The purpose of this randomized, two-arm and open label study is to demonstrate that the treatment of a daily dose of 3x10mg dydrogesterone orally is as effective and safe as the daily dose Crinone 8% intravaginal progesterone gel…
- Trial name
- LOTUS II (NCT02491437)
- Testing
- Dydrogesterone 30 mg, intravaginal progesterone gel 90 mg
- Where
- 40 sites in Australia, Belgium and 8 more
- Volunteers
- 1,034 people
- Sponsor
- Abbott
Pregnant Women
Early Progesterone Cessation After in Vitro Fertilization
There seems to be a general consensus on the supplementation of progesterone (P4) for luteal phase support (LPS) to all women after in vitro fertilization (IVF) treatment.
- Trial name
- NCT01177904
- Testing
- Cease progsterone at 5, control group: progesterone 8
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- IVI Madrid
Infertility, Male
Effect of Ejaculatory Abstinence on Semen Parameters in Male Factor Infertility Patients
The purpose of this study is to compare semen parameters with in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) when male factor infertility patients abstain from ejaculation more than 48 hours (routine care)…
- Trial name
- NCT04206800
- Testing
- Ejaculatory abstinence less than 24 hours
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Boston IVF
Infertility
Rekovelle PK Trial in Chinese Women
FE 999049 is a gonadotropin preparation containing recombinant human follicle stimulating hormone (rhFSH) under development by Ferring Pharmaceuticals.
- Trial name
- NCT04150861
- Testing
- Follitropin Delta
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Ferring Pharmaceuticals